Helix & CDC to Study the Role of Human Genetics in Vaccine Effectiveness
SAN MATEO, Calif., Jan. 4, 2023 /PRNewswire/ -- Helix, the leading population genomics and viral surveillance company in the nation, today announced a new Broad Agency Announcement (BAA) contract awarded by the Centers for Disease Control and Prevention (CDC) to better understand the role of human genetics in vaccine effectiveness particularly across SARS-CoV-2 variants. This new agreement extends the Company's viral sequencing leadership and further builds upon Helix's successful public-private partnership with the CDC.
- This new agreement extends the Company's viral sequencing leadership and further builds upon Helix's successful public-private partnership with the CDC.
- "The new research conducted by Helix and CDC will uncover meaningful information to better understand and inform what we know of long COVID and other adverse effects.
- The study will examine up to 10,000 individuals who have had breakthrough infections and severe COVID outcomes, despite being fully vaccinated.
- Currently, few studies formally address the host genetics of vaccine effectiveness, or the interplay between host and viral genetic variation in the context of breakthrough infections.